Bharat Immunological & Biological Corporation Ltd
Bharat Immunological & Biological Corporation Ltd Live Price Chart
Performance
| Previous Close | ₹ 17.04 |
| High | ₹ 17.15 |
| Volume | 18395 |
| 52W Range | ₹ 15.8 - ₹ 28.8 |
| Open | ₹ 16.7 |
| Low | ₹ 16.7 |
| Market Cap | ₹ 86 Cr |
Bharat Immunological & Biological Corporation Ltd Technicals
| 20 Day | ₹ 17.339 |
| 50 Day | ₹ 18.118 |
| 100 Day | ₹ 19.025 |
| 200 Day | ₹ 20.507 |
| 20 Day | ₹ 17.397 |
| 50 Day | ₹ 18.147 |
| 100 Day | ₹ 19.106 |
| 200 Day | ₹ 20.900 |
Bharat Immunological & Biological Corporation Ltd Fundamentals
| ROCE | -11.161 |
| P/E Ratio | -4.080 |
| P/B Ratio | 0.000 |
| Industry P/E | 0.000 |
| Debt to Equity | 40.033 |
| ROE | -22.951 |
| EPS | -4.180 |
| Dividend Yield | 0.000 |
| Book Value | -7.535 |
| Face Value | 10.000 |
Bharat Immunological & Biological Corporation Ltd Financials
| Particulars | Y202303 | Y202203 | Y202103 | Y202003 | Y201903 |
|---|---|---|---|---|---|
| Total Revenue | 47.4122 | 79.4903 | 87.0129 | 68.0202 | 87.8704 |
| Total Expenses | 70.2637 | 89.1777 | 111.2207 | 82.2234 | 95.2439 |
| Profit After Tax | -17.0567 | -8.7536 | -18.1127 | -10.2113 | -5.7931 |
Bharat Immunological & Biological Corporation Ltd Shareholding Pattern
| Promoter Holdings | 59.254 % |
| FIIs | 0.000 % |
| DIIs | 0.000 % |
| MutualFund | 0.000 % |
| Retail | 39.470 % |
| Others - | 1.276 % |
About Bharat Immunological & Biological Corporation Ltd
The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology. BIBCOL was incorporated in 1989. The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets. The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh. BIBCL installed a plant of 100 mln units. Commercial production of the OPV started from Jan'96. The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme. It has set up an R&D unit for the development of hepatitis B vaccine through transfer of technology from the US. In year 2006, the facility was up graded to meet the WHO cGMP & revised schedule M of Drugs & Cosmetics Act. In 2016, BIBCOL switched over to bOPV from tOPV . To add in product line, company diversified into Plasma derived medicines, and Oral Cholera Vaccine. ...
